Display options
Share it on

Clin Cases Miner Bone Metab. 2017 May-Aug;14(2):269-271. doi: 10.11138/ccmbm/2017.14.2.269. Epub 2017 Oct 25.

Periostin and sclerostin levels in juvenile Paget's disease.

Clinical cases in mineral and bone metabolism : the official journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases

Stergios A Polyzos, Polyzois Makras, Athanasios D Anastasilakis, Gesthimani Mintziori, Marina Kita, Athanasios Papatheodorou, Panagiotis Kokkoris, Evangelos Terpos

Affiliations

  1. Department of Endocrinology, Ippokration General Hospital, Thessaloniki, Greece.
  2. Department of Endocrinology and Diabetes, 251 Hellenic Air Force & VA General Hospital, Athens, Greece.
  3. Department of Endocrinology, 424 General Military Hospital, Thessaloniki, Greece.
  4. Department of Medical Research, 251 Hellenic Air Force & VA General Hospital, Athens, Greece.
  5. Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece.

PMID: 29263750 PMCID: PMC5726226 DOI: 10.11138/ccmbm/2017.14.2.269

Abstract

Juvenile Paget's disease (JPD) is a rare, autosomal recessive disorder featuring markedly increased serum alkaline phosphatase activity, indicative of greatly accelerated bone turnover throughout the skeleton. The main aim of this study was to evaluate circulating periostin and sclerostin levels in two adult patients with mild JPD (due to "Balkan" mutation). We measured periostin and sclerostin levels in a previously described woman and a newly diagnosed man with JPD, and 10 apparently healthy individuals, matched (1:5) to JPD patients for gender, age and body mass index. Sclerostin levels were similar between JPD patients and controls. Periostin levels were about 2.5 times higher in JPD patients. Periostin and sclerostin levels were negatively correlated (rs= -0.63; p=0.03). In conclusion, a trend towards higher periostin levels was observed in JPD patients, whereas sclerostin levels were similar to controls.

Keywords: CTX; PINP; juvenile Paget’s disease; periostin; sclerostin

Conflict of interest statement

Conflict of interest All Authors have no conflicts of interest.

References

  1. Rheumatology (Oxford). 2015 May;54(5):908-14 - PubMed
  2. Bone. 2012 Jul;51(1):153-7 - PubMed
  3. J Bone Miner Metab. 2010 Nov;28(6):706-12 - PubMed
  4. Clin Biochem. 2009 Jul;42(10-11):965-9 - PubMed
  5. Osteoporos Int. 2012 Mar;23(3):1171-6 - PubMed
  6. Proc Natl Acad Sci U S A. 2012 Sep 11;109(37):15048-53 - PubMed
  7. Arch Ophthalmol. 2010 Jun;128(6):698-703 - PubMed
  8. Endocrine. 2016 Jan;51(1):4-6 - PubMed
  9. J Bone Miner Res. 2003 Dec;18(12):2095-104 - PubMed
  10. N Engl J Med. 2002 Jul 18;347(3):175-84 - PubMed
  11. J Clin Endocrinol Metab. 2014 Mar;99(3):703-7 - PubMed
  12. Clin Rheumatol. 2017 Apr;36(4):925-928 - PubMed
  13. Horm Metab Res. 2014 Feb;46(2):145-9 - PubMed
  14. Clin Biochem. 2012 Jan;45(1-2):43-8 - PubMed
  15. Mol Cell Endocrinol. 2016 Sep 5;432:75-82 - PubMed
  16. J Clin Endocrinol Metab. 2014 Jul;99(7):2533-9 - PubMed

Publication Types